Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Aug 29;25(1):222.
doi: 10.1186/s12894-025-01913-5.

Stem cell therapy for erectile dysfunction: promise or reality? - a systematic review and meta-analysis of clinical trials

Samet Senel  1 , Ahmet Halil Sevinc  1 , Huseyin Gultekin  2 , Abduvaliyev Jaxongir Ravshanbekovich  3 , Huseyin Besiroglu  4 , Murat Dursun  1 , Ates Kadioglu  5
Affiliations
Meta-Analysis

Stem cell therapy for erectile dysfunction: promise or reality? - a systematic review and meta-analysis of clinical trials

Samet Senel et al. BMC Urol. .

Abstract

Background: The outcomes of clinical trials on stem cell therapy (SCT) on erectile dysfunction (ED) treatment are promising but there is still no conclusive evidence regarding its efficacy. The aim of this meta-analysis is to compile studies that assess the effectiveness of SCT on ED to reach a more reliable conclusion.

Methods: The meta-analysis was registered to PROSPERO (CRD42024540511). We utilized the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline to report the outcomes. Articles published from January 2000 to May 2024 were included for systematic review. We performed a systematic search using keywords: "stem cell" AND ("erectile dysfunction" OR "erectile function" OR "erection" OR "impotence").

Results: We initially identified 2,013 studies in full publications or abstracts using the search terms. Eleven studies were included in systematic review and six of them were included in meta-analysis. Most studies included in systematic review reported improvements in erectile function following intracavernosal SCT. The meta-analysis revealed significant improvements at six months in international index of erectile function-5 (IIEF-5), international index of erectile function-erectile function domain) IIEF-EF, erectile hardness score (EHS), and peak systolic velocity (PSV) (p < 0.05). End-diastolic velocity (EDV) increased significantly at 3 months (p = 0.031) but not at six months (p = 0.868). Heterogeneity ranged from low to high (I² = 0-71.2%). No significant publication bias was detected (Egger's test p > 0.05).

Conclusion: Intracavernosal SCT may increase scores on the questionnaires evaluated compared to baseline at six months which currently represent the longest reported follow-up duration but comparative trials with longer follow-up periods are needed to draw more definitive conclusions and reveal long-term effect.

Keywords: ED; Erectile dysfunction; Regenerative therapy; Stem cell.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flowchart—study selection with inclusion and exclusion criteria of reviewed studies. PRISMA, Preferred reporting items for systematic reviews and meta-analysis
Fig. 2
Fig. 2
The forest plots of the studies comparing: A baseline and third-month PSV value (p value for heterogeneity: 0.15; Q = 3.72; I2 = 46.31) (B) baseline and sixth-month PSV value (p value for heterogeneity: 0.03; Q = 6.96; I2 = 71.24)
Fig. 3
Fig. 3
The forest plots of the studies comparing: A baseline and third-month EDV value (p value for heterogeneity: 0.28; Q = 2.57; I2 = 22.11) (B) baseline and sixth-month EDV value (p value for heterogeneity: 0.03; Q = 6.76; I2 = 70.40)
Fig. 4
Fig. 4
The forest plots of the studies comparing: A baseline and third-month IIEF-5 value (p value for heterogeneity: 0.157; Q = 2.01; I2 = 50.16) (B) baseline and sixth-month IIEF-5 value (p value for heterogeneity: 0.151; Q = 2.07; I2 = 51.59)
Fig. 5
Fig. 5
The forest plots of the studies comparing: A baseline and third-month IIEF value (p value for heterogeneity: 0.424; Q = 0.64; I2 < 0.0001) (B) baseline and sixth-month IIEF value (p value for heterogeneity: 0.391; Q = 0.74; I2 < 0.0001)
Fig. 6
Fig. 6
The forest plots of the studies comparing baseline and sixth-month IIEF-EF value (p value for heterogeneity: 0.387; Q = 0.75; I2 < 0.0001)
Fig. 7
Fig. 7
The forest plots of the studies comparing: A baseline and third-month EHS value (p value for heterogeneity: 0.08; Q = 3.03; I2 = 66.99) (B) baseline and sixth-month EHS value (p value for heterogeneity: 0.69; Q = 0.15; I2 < 0.0001)
See this image and copyright information in PMC

References

    1. Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010;7(3):445–7. - PubMed
    1. NIH Consensus Conference. Impotence. JAMA. 1993;270:83. - PubMed
    1. Fisher WA, Eardley I, McCabe M, Sand M. Erectile dysfunction (ED) is a shared sexual concern of couples I: couple conceptions of ED. J Sex Med. 2009;6(10):2746–60. - PubMed
    1. Al Demour S, Adwan S, Jafar H, Rahmeh R, Alhawari H, Awidi A. Safety and efficacy of 2 intracavernous injections of allogeneic wharton’s jelly-derived mesenchymal stem cells in diabetic patients with erectile dysfunction: phase 1/2 clinical trial. Urol Int. 2021;105(11–12):935–43. - PubMed
    1. Chung DY, Ryu JK, Yin GN. Regenerative therapies as a potential treatment of erectile dysfunction. Investig Clin Urol. 2023;64(4):312–24. - PMC - PubMed

LinkOut - more resources